Boron tribromide → HCID 135796747, compound

HRID 333708Notes

Reaction equation

HRID 333708 reaction equation
C[O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[C:9]1[N:10]=[C:11]([N:18]2[CH2:23][CH2:22][N:21]([C:24]([O:26][CH2:27][CH:28]([CH3:30])[CH3:29])=[O:25])[CH2:20][CH2:19]2)[C:12]2[S:17][CH:16]=[CH:15][C:13]=2[N:14]=1.B(Br)(Br)Br.C([O-])(O)=O.[Na+]>C(Cl)Cl>[OH:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[C:9]1[N:10]=[C:11]([N:18]2[CH2:19][CH2:20][N:21]([C:24]([O:26][CH2:27][CH:28]([CH3:30])[CH3:29])=[O:25])[CH2:22][CH2:23]2)[C:12]2[S:17][CH:16]=[CH:15][C:13]=2[N:14]=1

Participants

5

Procedure

A solution of isobutyl 4-(2-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.11 g, 0.26 mmol) in CH2Cl2 (2 mL) was cooled to −50° C., and a solution of BBr3 in CH2Cl2 (1 M, 1.5 mL, 1.5 mmol) was slowly added. The reaction was allowed to gradually warm to room temperature over 16 h, and saturated aqueous NaHCO3 was slowly added. The organic layer was separated, washed with water, dried over Na2SO4, and concentrated under vacuum. The residue was purified by preparative reverse phase HPLC using 10%-99% CH3CN (0.035% TFA)/H2O (0.05% TFA) to give isobutyl 4-(2-(2-hydroxyphenyl)thieno[3,2-d]pyrimidin-4-yl)piperazine-1-carboxylate. LC/MS: m/z 413.3 (M+H)+ at 3.33 min (10%-99% CH3CN (0.035% TFA)/H2O (0.05% TFA)).

Workup

  1. customThe organic layer was separated
  2. washwashed with water
  3. dry with materialdried over Na2SO4
  4. concentrationconcentrated under vacuum
  5. customThe residue was purified by preparative reverse phase

Sources & evidence

ORD record
ord-52d756d0d7bd4405b233ee0ac4407d64
Source dataset
uspto-grants-2014_11
Patent number
US08883781B2

Reaction notes

Loading…